Skip to main content

Table 1 Baseline characteristics and CMR findings

From: Diffuse myocardial fibrosis is associated with impaired myocardial strain and disease activity in rheumatoid arthritis: a cardiovascular magnetic resonance study

  Controls
N = 39
RA
N = 39
P value
Female sex, n (%) 28 (72) 28 (72) 1.00
Age, years 49 ± 12 50 ± 12 0.65
Hypertension, n (%) 2 (5) 5 (13) 0.65
Diabetes, n (%) 0 1 (3) -
Hyperlipidaemia, n (%) 5 (13) 6 (15) 0.75
BMI, kg/m2 24 ± 4 26 ± 5 0.13
DAS28-CRP (median, IQR) N/A 3.3 ± 1.3 -
ESR, mm/hr (median, IQR) N/A 15 (9-19) -
CRP, mg/L (median, IQR) 1 (1-2) 9 (4-13) < 0.001
Hemoglobin, g/L 13 ± 1 13 ± 1 0.47
Duration of RA, years (median, IRQ) N/A 7 (4-11) -
Duration of DMARDs, years (median, IQR) N/A 4 (3-6) -
LVEDV indexed to BSA, ml/m2 78 ± 15 80 ± 16 0.63
LVESV indexed to BSA, ml/m2 24 ± 16 23 ± 9 0.62
LVEF, % 73 ± 5 72 ± 7 0.25
LV Mass indexed to BSA, g/m2 52 ± 11 54 ± 12 0.34
LA size, mm 27 ± 5 32 ± 5 < 0.001
Mid SA circumferential strain -19.0 ± 1.2 -17.1 ± 1.2 < 0.001
Peak diastolic circumferential strain rate (s-1) 117 ± 18 85 ± 18 < 0.001
Presence of LGE (%) 0 18 (46) -
Volume fraction of LGE > 2SD (%) 0 3.7 ± 0.4 -
STIR T2 Ratio 1.5 ± 0.1 1.6 ± 0.2 0.07
  1. Continuous data are mean ± SD unless otherwise indicated. BMI, body mass index; CRP, C-reactive protein; DMARD, disease modifying anti-rheumatic drug; ESR, erythrocyte sedimentation rate; IQR, interquartile range; LA, left atrium; LGE, late gadolinium enhancement; LV, left ventricle/ventricular; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; RA, rheumatoid arthritis; SA, short axis; STIR, short Tau inversion recovery